Biotechnology News

Today, Novonesis will initiate the first tranche (the “First Tranche”) of the EUR 1 billion multi-year share buyback program announced in Company Announcement No. 14, on August 19, 2026. Under the...

COPENHAGEN, Denmark, September 14, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on September 1, 2026, under which the Company will repurchase...

KØBENHAVN, Danmark, 14. september 2026 – Bavarian Nordic A/S (OMX: BAVA) offentliggør transaktioner under aktietilbagekøbsprogrammet, der blev iværksat den 1. september 2026, hvorunder selskabet vil...

All 24 patients completed treatment with no dose-limiting toxicities, no Grade 3 or higher adverse events related to JNJ-1900 (NBTXR3 or to the injection procedure, and intratumoral injection was...

L’ensemble des 24 patients a été traité sans toxicité limitant la dose, sans événement indésirable de grade 3 ou supérieur liés à JNJ-1900 (NBTXR3) ou à la procédure d’injection, et l’injection...

Allschwil, Switzerland, September 14, 2026 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe...

Allschwil, 14. September 2026 Basilea Pharmaceutica AG, Allschwil (SIX: BSLN), ein biopharmazeutisches Unternehmen mit bereits vermarkteten Produkten und dem Ziel, Patientinnen und Patienten zu...

EMERYVILLE, Calif., Sept. 11, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and...

CAMBRIDGE, Mass., Sept. 11, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company leveraging a novel Oligonucleotide Promoted Editing of RNA (OPERA®) platform...

NORWOOD, Mass., Sept. 11, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP), a clinical-stage company focused on developing new therapies in oncology and obesity, today...